{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-330804","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2026-08-03T21:06:22+00:00","discovered_at":"2026-08-03T21:08:00.866688+00:00","generated_at":"2026-08-03T21:08:11.642273+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Stoke Therapeutics files prospectus supplement for up to $200M ATM offering","bullets":["Filed prospectus supplement on Aug 3, 2026 to sell up to $200M of common stock.","Shares offered under existing Controlled Equity Offering Sales Agreement with Cantor Fitzgerald.","Prospectus supplement part of automatic shelf registration statement filed March 18, 2026.","Legal opinion of Fenwick & West LLP filed as Exhibit 5.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-330804","json":"https://secwatch.observer/filing/0001193125-26-330804.json","markdown":"https://secwatch.observer/filing/0001193125-26-330804.md","text":"https://secwatch.observer/filing/0001193125-26-330804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/0001193125-26-330804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/d135735d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T21:08:11.642273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}